Enduring non-rapid eye movement sleep fragmentation following methotrexate chemotherapy in cancer-naïve mice
SLEEP · 2025
DOI: 10.1093/sleep/zsaf073 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLEEP, 2025. Verfasst von Leah Boyd und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA. Hauptthemen laut MEDLINE: Methotrexate, Sleep Deprivation, Antimetabolites, Antineoplastic, Sleep Stages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support Grant, NIH-NCI.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Study Objectives Sleep disruption is common in people with cancer and survivors, but understanding the mechanisms driving these problems is difficult due to heterogeneity among cancers, patients, and treatment modalities. We investigated whether the common antifolate chemotherapeutic agent methotrexate (MTX) promotes changes in sleep independent of cancer in adult mice.
Methods
Adult mice (>7 weeks old, both sexes, n = 13) were exposed to either a clinically relevant chemotherapy regimen with methotrexate (n = 7) or saline (control, n = 6) accompanied by continuous EEG/EMG telemetry recording. Sleep states were scored as either wake, non-rapid eye movement (NREM) sleep, or REM sleep in 5-second epochs weekly during MTX or saline treatment and then 2 weeks following the last injection to examine enduring changes in sleep–wake cycles.
Results
MTX exposure caused NREM sleep fragmentation, indicated by (1) shorter and more frequent NREM sleep bouts, (2) more transitions between wake and NREM sleep, and (3) more accumulated NREM sleep bouts over time. These effects were first detected after the second MTX injection and lasted into the 2-week follow-up recording. MTX did not alter delta power in NREM sleep, indicating no changes to sleep quality. The total time spent in each vigilance state remained unaffected by MTX use. Finally, when given MTX, male mice displayed more fragmented sleep compared to female mice.
Conclusions
Methotrexate promotes NREM sleep fragmentation, without affecting sleep quality or time spent asleep. This effect is stronger in males. These data suggest that chemotherapy can cause long-term sleep disruption independent of cancer presence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Palo Alto, CA, USA.
ORCID-Profile: Jeremy C Borniger
Förderung
- NCI NIH HHS
- Cancer Center Support Grant
- NIH-NCI
- NIH
- NCI
- NIH Cancer Center Support
Zitieren
APA
Boyd, L., Berisha, A., Gomez, A. M., Gibson, E. M., & Borniger, J. C. (2025). Enduring non-rapid eye movement sleep fragmentation following methotrexate chemotherapy in cancer-naïve mice. SLEEP. https://doi.org/10.1093/sleep/zsaf073
Vancouver
Boyd L, Berisha A, Gomez AM, Gibson EM, Borniger JC. Enduring non-rapid eye movement sleep fragmentation following methotrexate chemotherapy in cancer-naïve mice. SLEEP. 2025. doi:10.1093/sleep/zsaf073
BibTeX
@article{Boyd2025,
author = {Boyd, Leah and Berisha, Adrian and Gomez, Adrian M and Gibson, Erin M and Borniger, Jeremy C},
title = {Enduring non-rapid eye movement sleep fragmentation following methotrexate chemotherapy in cancer-naïve mice},
journal = {SLEEP},
year = {2025},
doi = {10.1093/sleep/zsaf073}
}
EUVIMED